Lymphotactin as an adjuvant

Details Lymphotactin as an adjuvant Lymphotactin as an adjuvant

1998-12-17

2000-11-28

Mertz, Prema

Drug, bio-affecting and body treating compositions

Lymphokine

514 2, 514 8, 514 12, 514885, A61K 3819

Patent

active

061531820

ABSTRACT:
Compositions of lymphotactin in cellular immune enhancing amounts may advantageously be administered at very low levels in conjunction with vaccines to provide improved immune response, Suggested dosage such as 1 to 10 .eta.g in small animals and from 10 .mu.g to 10 mg in large mammals may be administered.

REFERENCES:
patent: 5985580 (1999-11-01), Kelner et al.

Affiliated with

Also associated with

Rating

Lymphotactin as an adjuvant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lymphotactin as an adjuvant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lymphotactin as an adjuvant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1722067